LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy. The results from a dose escalation trial of infusion of ABRAXANE directly into the bladder in these patients who have failed standard chemotherapy are being presented for the first time as a late-breaker during an oral session on June 1st at the 2010 American Urological Association Annual Meeting in San Francisco.
